Follytropyn beta | Puregon solution for in / m and p / kozh. introducing 100 IU 0.5 ml vials of 5 pcs.

Latin name

Puregon

Release form

Solution for dkozhnogo introduction

Packaging

1 cartridge

Pharmacological action

Puregon - follicle-stimulating. Puregon makes up for FSH deficiency. Regulates the normal growth and maturation of follicles, the synthesis of sex steroid hormones.

Contraindications

Hypersensitivity, tumors of the ovaries, breast, uterus, pituitary or hypothalamus, primary ovarian failure, ovarian cysts or ovarian enlargement, not associated with polycystic ovary syndrome, impaired anatomy of the genital organs or uterine fibroma, incompatible with pregnancy.

Use during pregnancy and lactation

Contraindicated in pregnancy. Lactating women should abandon breastfeeding.

Composition

1 cartridge contains:

Active ingredient: follitropine-beta 100 IU.

Dosage and administration of

Intramuscularly, subcutaneously (slowly).

Anovulation - start with daily administration of 50–75 IU for 7 days, in the absence of an ovarian response, the dose is gradually increased (the optimal daily increase in plasma estradiol concentration is 40–100%) when the dominant follicle reaches a diameter of 18 mm or an estradiol level of 300–900 PG / ml, Puregon is canceled and human chorionic gonadotropin is administered. The induction of ovarian superovulation during in vitro fertilization in the first 4 days is 100-200 IU, then the dose is selected individually, based on the reaction of the ovaries, usually 75-375 IU per day for 1-2 weeks is usually sufficient in the presence of 3 follicles with a diameter of 16-20 mm and plasma estradiol concentration 300-400 pg / ml / follicle, the final phase of follicular maturation is stimulated by the human chorionic gonadotropin after 34–35 hours the eggs are aspirated.

Side effects

Ovarian hyperstimulation (abdominal pain, nausea, diarrhea, enlarged ovaries and their cysts, rarely - rupture of ovarian cysts, ascites, hydrothorax, weight gain) at the injection site - edema, pain, redness, itching. After ovulation induction, the risk of developing multiple and in vitro fertilization - ectopic pregnancy.

Drug Interaction

Co-administration of Puregon and clomiphene may enhance ovarian response.

A higher dose of Puregon may be required after pituitary desensitization with GnRH agonists to achieve sufficient ovarian response.

Pharmaceutically incompatible with other medicines.

overdose

There is no evidence of an acute overdose of Puregon. The use of FSH at high doses can lead to the development of ovarian hyperstimulation syndrome, the symptoms of which are described above.

Treatment: In the event of symptoms of unwanted hyperstimulation (not related to the induction of superovulation during in vitro fertilization), the administration of Puregon should be discontinued. In this case, measures should be taken to prevent pregnancy and to refuse the introduction of HG, which may aggravate the undesirable effects. Treatment should be performed to eliminate the symptoms of ovarian hyperstimulation syndrome.

Storage conditions

The drug should be stored in a dark place, out of reach of children at a temperature of 2 ° to 8 РC, do not freeze.

Expiration

2 Year

Deystvuyuschee substances

Follytropyn beta

Pharmacy terms

Prescription



Dosage Form A dosage form

injection

N.V. V.Organon, the Netherlands